According to the recent research report titled ‘GLOBAL Dna Vaccines Market 2019-2027’, available with Market Study Report, global DNA vaccines market is projected to witness a y-o-y growth rate of 42.03% during 2019-2027.
 

Increasing cases of infectious and chronic diseases, and surging development of new vaccines are the major factors driving global DNA vaccines market growth. Moreover, increased utilization of vaccines in animal healthcare is adding considerable traction to business development.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2487414/
 

Growing requirement of steady vaccines that are easy to store and transport, coupled with increasing number of clinical trials on humans, as well as escalating demand for gene therapy supplement are also enhancing the overall market outlook.
 

For those uninitiated, DNA vaccines are third-generation vaccines which comprises DNA accountable for coding of certain proteins (antigens) from pathogens. The cells (humans / animals) are inoculated with genetically engineered DNA so that they can produce antigens with the help of a defensive immunological response.
 

Besides, unlike traditional vaccines these vaccines use DNA from infectious species only, pose no possible risk of infection, and have both cell-mediated and humoral immunity. DNA vaccines can trigger a wide variety of immune responses and are thus thoroughly studied for the possible benefits of curing diseases such as HIV/AIDS, cancer, and others, further enhancing worldwide DNA vaccines industry scope.
 

Considering the restraints, stringent government norms and lack of legal & ethical framework may hamper the industry expansion over the analysis period.
 

Elaborating on type, global DNA vaccines market is divided into human and animal DNA vaccine. Based on application spectrum, the industry is bifurcated into veterinary and human diseases. Moving on to technology type, the market is split into plasmid DNA delivery and plasmid DNA vaccines.
 

Citing the regional landscape, North America currently holds considerable portion of global DNA vaccines market share, attributable to increasing investments towards encouraging development of human DNA vaccines in economies such as Canada and the U.S. For instance, as per National Center for Biotechnology Information, USD 440 million was raised by the Canadian government in the year 2015 for development and advancement of DNA vaccines in the region, concentrating on both animals and humans.
 

Major contenders impacting global DNA vaccines market dynamics are Eurogentec S.A., Xenetic Biosciences Inc., Inovio Pharmaceuticals Inc., Dendreon Pharmaceuticals LLC (Sanpower Group), Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline Inc., Madison Vaccines Inc. (MVI), Merial Limited (Boehringer Ingelheim), Sanofi S.A., Vical Inc., Merck & Co., VGXI Inc., Zoetis Inc., and Novartis AG.